Sector Gamma AS reported 39 positions worth $456.68M for the quarter ended Jun 30, 2026, up 8.7% on the prior quarter. It opened 6 new positions, added to 18, trimmed 11 and exited 8. Its largest holding is Bristol Myers Squibb Co at 9.2% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | +33.6K | – | $16.84M | 3.69% |
| REGN Regeneron Pharmaceuticals, Inc. | +15.8K | – | $9.84M | 2.15% |
| IQV Iqvia Holdings Inc. | +37.7K | +93.7% | $7.29M | 3.3% |
| MDT Medtronic plc | +71.8K | +25.6% | $5.61M | 6.04% |
| ABT Abbott Laboratories | +59.9K | +68.4% | $5.44M | 2.93% |
| GEHC GE HealthCare Technologies Inc. | +81.4K | +64.4% | $5.21M | 2.91% |
| BSX Boston Scientific Corp | +121.1K | – | $5.17M | 1.13% |
| QGEN Qiagen N.V. | +125.3K | +77.1% | $4.90M | 2.46% |
| TVTX Travere Therapeutics, Inc. | +80.0K | – | $4.54M | 0.995% |
| CYTK Cytokinetics Inc | +45.0K | – | $3.83M | 0.839% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| UNH Unitedhealth Group Inc | -36.4K | -100.0% | $9.86M | Exited |
| BIIB Biogen Inc. | -35.9K | -39.9% | $7.76M | 2.56% |
| AMGN Amgen Inc | -20.9K | -44.3% | $7.56M | 2.08% |
| GILD Gilead Sciences, Inc. | -53.2K | -100.0% | $7.42M | Exited |
| LNTH Lantheus Holdings, Inc. | -93.3K | -100.0% | $7.08M | Exited |
| BRKR Bruker Corp | -101.7K | -40.0% | $6.12M | 2.01% |
| BMY Bristol Myers Squibb Co | -101.8K | -12.3% | $5.86M | 9.16% |
| MRK Merck & Co., Inc. | -43.3K | -16.6% | $5.57M | 6.11% |
| CAH Cardinal Health Inc | -14.2K | -25.9% | $3.38M | 2.12% |
| INCY Incyte Corp | -29.8K | -14.8% | $3.37M | 4.24% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | +33.6K | $16.84M | 3.69% |
| REGN Regeneron Pharmaceuticals, Inc. | +15.8K | $9.84M | 2.15% |
| BSX Boston Scientific Corp | +121.1K | $5.17M | 1.13% |
| TVTX Travere Therapeutics, Inc. | +80.0K | $4.54M | 0.995% |
| CYTK Cytokinetics Inc | +45.0K | $3.83M | 0.839% |
| NTLA Intellia Therapeutics, Inc. | +185.2K | $3.13M | 0.686% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| UNH Unitedhealth Group Inc | -36.4K | $9.86M | 2.35% |
| GILD Gilead Sciences, Inc. | -53.2K | $7.42M | 1.77% |
| LNTH Lantheus Holdings, Inc. | -93.3K | $7.08M | 1.69% |
| HUM Humana Inc | -19.2K | $3.33M | 0.793% |
| BBIO BridgeBio Pharma, Inc. | -44.3K | $3.29M | 0.782% |
| DNLI Denali Therapeutics Inc. | -162.7K | $3.12M | 0.744% |
| COGT Cogent Biosciences, Inc. | -80.0K | $3.08M | 0.733% |
| ARWR Arrowhead Pharmaceuticals, Inc. | -30.0K | $1.88M | 0.448% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | BMY Bristol Myers Squibb Co | Healthcare | 726.1K | $41.84M | 9.16% | -101.8K | -12.3% | Reduced | 0.04% |
| 2 | MRK Merck & Co., Inc. | Healthcare | 217.0K | $27.89M | 6.11% | -43.3K | -16.6% | Reduced | 0.01% |
| 3 | MDT Medtronic plc | Healthcare | 352.4K | $27.57M | 6.04% | +71.8K | +25.6% | Added | 0.03% |
| 4 | PFE Pfizer Inc | Healthcare | 1.00M | $24.18M | 5.3% | -87.2K | -8.0% | Reduced | 0.02% |
| 5 | INCY Incyte Corp | Healthcare | 170.8K | $19.36M | 4.24% | -29.8K | -14.8% | Reduced | 0.08% |
| 6 | ELV Elevance Health, Inc. | Healthcare | 44.5K | $17.21M | 3.77% | +537 | +1.2% | Added | 0.02% |
| 7 | BMRN Biomarin Pharmaceutical Inc | Healthcare | 294.9K | $16.88M | 3.7% | +55.0K | +22.9% | Added | 0.15% |
| 8 | TMO Thermo Fisher Scientific Inc. | Healthcare | 33.6K | $16.84M | 3.69% | +33.6K | – | New | 0.01% |
| 9 | CVS CVS HEALTH Corp | Healthcare | 155.3K | $16.07M | 3.52% | +20.0K | +14.8% | Added | 0.01% |
| 10 | IQV Iqvia Holdings Inc. | Healthcare | 77.9K | $15.06M | 3.3% | +37.7K | +93.7% | Added | 0.05% |
| 11 | IONS Ionis Pharmaceuticals Inc | Healthcare | 189.5K | $15.02M | 3.29% | +20.0K | +11.8% | Added | 0.11% |
| 12 | BDX Becton Dickinson & Co | Healthcare | 93.2K | $14.10M | 3.09% | +10.6K | +12.8% | Added | 0.03% |
| 13 | ABT Abbott Laboratories | Healthcare | 147.4K | $13.38M | 2.93% | +59.9K | +68.4% | Added | 0.01% |
| 14 | GEHC GE HealthCare Technologies Inc. | Healthcare | 207.9K | $13.31M | 2.91% | +81.4K | +64.4% | Added | 0.05% |
| 15 | ZBH Zimmer Biomet Holdings, Inc. | Healthcare | 142.3K | $12.25M | 2.68% | -13.5K | -8.7% | Reduced | 0.07% |
Tip. Select a row to see that position’s full history at Sector Gamma As.
As of its Q2 2026 13F filing, Sector Gamma AS’s five largest positions were Bristol Myers Squibb Co (BMY) at 9.2%, Merck & Co., Inc. (MRK) at 6.1%, Medtronic plc (MDT) at 6.0%, Pfizer Inc (PFE) at 5.3%, Incyte Corp (INCY) at 4.2% of the reported portfolio.
Sector Gamma AS reported a 13F portfolio worth $456.68M across 39 positions for Q2 2026. That is up 8.7% from the previous quarter.
Its largest purchases by value were Thermo Fisher Scientific Inc. ($16.84M), Regeneron Pharmaceuticals, Inc. ($9.84M), Iqvia Holdings Inc. ($7.29M). It opened 6 new positions.
Its largest sales by value were Unitedhealth Group Inc ($9.86M), Biogen Inc. ($7.76M), Amgen Inc ($7.56M). It exited 8 positions entirely.
From the Form 13F-HR reports Sector Gamma AS files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.